ALPHE — Pherecydes Pharma SA Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes
Brief: PHERECYDES Pharma Strengthens Its Corporate Links With ERYTECH To Prepare Strategic Combination
Brief: Erytech Says Pherecydes Will Be Merged Into Co
Brief: Erythech Pharma End-March Cash And Cash Equivalents Of EUR 30.5 Million
Brief: Erytech And Pherecydes Announce Proposed Combination Intending To Create Global Leader In Extended Phage Therapies
Brief: Pherecydes Pharma: 1st Registration Of Phagogram As In Vitro Diagnostic Test
Brief: Pherecydes Pharma: Positive Preclinical Results For Inhaled Phage Therapy
Brief: Pherecydes Pharma Appoints Didier Hoch As Chairman And CEO
Brief: Pherecydes Pharma FY Operating Loss Widens To EUR 4.32 Million
Brief: Pherecydes Pharma Partners With Spain's Navarrabiomed
Brief: Pherecydes Pharma Granted New Patent For Its Anti-Pseudomonas Aeruginosa Phages In Europe
Brief: Pherecydes Pharma And Bioaster To Collaborate In Treatment Of Bacteremia
Brief: Pherecydes Pharma Granted Patent For Its Anti-Pseudomonas Aeruginosa Phages In China
Brief: Pherecydes Pharma SA Says Guy-Charles Fanneau De La Horie Has Been Appointed Chief Executive Officer
Brief: Pherecydes Pharma Receives Go-Ahead From Ethics Committee For PhagoDAIR Study
Brief: Pherecydes Pharma Get ANSM Approval For PhagoDAIR Programme